Applied Filters
The future of precision medicine part 3: translation from research to the clinic
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis.
Gene-editing: a block on further development
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds.
How the EPO treats personalised healthcare patents
The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, but various aspects of these inventions are patentable in Europe, as Laurence Gainey of HGF explains.
New standards for stem cells
Costa Rica has released new rules for the clinical investigation of adult stem cells, as María del Pilar López and Esteban Monge of Zürcher Lawyers report.
Patenting microorganisms in Mexico
Mexico has international depositary authority (IDA) status under the Budapest Treaty, which speeds up the patent process for microorganisms. Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reviews the impact of the IDA on biotech patents in the country.
LSIPR 50 2018: Frank Kalkbrenner
Frank Kalkbrenner was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Bryan Roberts
Bryan Roberts was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Jim Tananbaum
Jim Tananbaum was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
LSIPR 50 2018: Kim Nasmyth
Kim Nasmyth was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2018: Tedros Ghebreyesus
Tedros Ghebreyesus was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.
